A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair

Duffy, M. J., O'Kane, C. M., Stevenson, M., Young, I. S., Harkin, D. W., Mullan, B. A., & McAuley, D. F. (2015). A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair. Intensive Care Medicine Experimental, 3, [30]. DOI: 10.1186/s40635-015-0050-5

Published in:
Intensive Care Medicine Experimental

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2015 The Authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair

Martin J Duffy1,2, Cecilia M O’Kane2, Michael Stevenson3, Ian S Young3, Denis W Harkin4, Brian A Mullan1,2 and Daniel F McAuley1,2*

Abstract

Background: Open AAA repair is associated with ischaemia-reperfusion injury where systemic inflammation and endothelial dysfunction can lead to multiple organ injury including acute lung injury. Oxidative stress plays a role that may be inhibited by ascorbic acid.

Methods: A double blind, allocation concealed, randomized placebo-controlled trial was performed to test the hypothesis that a single bolus dose (2g) of intra-operative parenteral ascorbic acid would attenuate biomarkers of ischaemia-reperfusion injury in patients undergoing elective open AAA repair.

Results: Thirty one patients completed the study; 18 received placebo and 13 ascorbic acid. Groups were comparable demographically. Open AAA repair caused an increase in urinary Albumin:Creatinine Ratio (ACR) as well as plasma IL-6 and IL-8. There was a decrease in exhaled breath pH and oxygenation. Lipid hydroperoxides were significantly higher in the ascorbic acid group following open AAA repair. There were no other differences between the ascorbic acid or placebo groups up to 4 hours after removal of the aortic clamping.

Conclusions: Open AAA repair caused an increase in markers of systemic endothelial damage and systemic inflammation. Administration of 2g parenteral ascorbic acid did not attenuate this response and with higher levels of lipid hydroperoxides post-operatively a pro-oxidant effect could not be excluded.

Trial registration: ISRCTN27369400

Keywords: Ascorbic Acid; Ichaemia-Reperfusion injury; Abdominal aortic aneurysm; Perioperative anaesthesia; Perioperative critical care

Background

Open Abdominal Aortic Aneurysm (AAA) repair necessitates the use of an aortic cross-clamp which causes an ischaemia-reperfusion injury to remote tissues which can lead to multiple organ dysfunction syndrome (MODS) including acute lung injury (ALI) and death [1].

Ischaemia-reperfusion injury is associated with an increase in oxidative stress through the accumulation of reactive oxygen species (ROS) which can up-regulate pro-inflammatory pathways contributing to remote organ dysfunction [2,3]. Lipid peroxidation is central in oxidative stress and can be measured using end products [4]. Ischaemia leads to endothelial activation with increased expression of endothelial adhesion molecules [5].

© 2015 Duffy et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Reperfusion enhances this response and is associated with up-regulation of plasma cytokines [6] and increased leucocyte interaction [7]. Increased urinary albumin:creatinine ratio (ACR) has been associated with impaired endothelial-dependent vasodilation [8], a surrogate measure of endothelial dysfunction [9]. There is evidence of systemic endothelial dysfunction as measured by urinary albumin:creatinine ratio (ACR) in patients undergoing open AAA repair [10] correlating with outcome from ALI in this setting [11,12]. In patients undergoing open AAA repair a rise in ACR measured 4 hours following induction of anaesthesia predicted those at risk of post-operative pulmonary dysfunction [13].

Pulse Wave Analysis (PWA) provides a bedside measure of systemic endothelial function and has been shown to independently predict mortality in the critically ill [14]. Pulmonary dead-space fraction is increased in the acute respiratory distress syndrome (ARDS) and may reflect the extent of pulmonary endothelial dysfunction [15].

Ascorbic acid can act as a reactive oxygen species (ROS) scavenger [16,17]. Low ascorbic acid levels have been described in humans subjected to ischaemia-reperfusion injury during cardiac surgery [18,19] and are associated with acute inflammation [20]. Ascorbic acid attenuates endothelial dysfunction in animal models of acute lung injury (ALI) [21] a condition characterized by uncontrolled inflammation [22]. Ascorbic acid can improve endothelial function [23] by inhibiting apoptosis [24], and preserving endothelial barrier function [25]. As a scavenger it reduces oxidative uncoupling of endothelial nitric oxide synthase (eNOS) leading to further ROS production [26,27]. The hypothesis in this study was that an intra-operative bolus dose (2g) of parenteral ascorbic acid may attenuate markers of oxidative stress, inflammation and endothelial dysfunction caused by open AAA repair.

Methods
This was a single centre, double blind allocation concealed, randomized placebo-controlled trial. The protocol was approved by the local institution, the UK Medicines and Healthcare products Regulatory Agency and the regional ethics committee. Written informed consent was obtained from each participant prior to study commencement. The trial is registered with www.isrctn.com (ISRCTN27369400).

The study was performed at the Royal Victoria Hospital, Belfast, a tertiary care teaching hospital. Adults undergoing elective open AAA repair were eligible for enrollment. Exclusion criteria were age less than 18 years old, a history of hyperoxaluria or glucose-6-phosphate dehydrogenase deficiency, prior antioxidant therapy, known allergy to ascorbic acid or to anaesthetic agents specified in anaesthetic protocol, participation in another intervention trial within 30 days or a lack of consent.

Patients were randomly assigned to receive intraoperative intravenous ascorbic acid 2 g in 250 ml 0.9% saline or 250 ml 0.9% saline placebo over 15 minutes following induction of anaesthesia. Block randomization was performed by an independent statistician. The randomization assignments were concealed in sealed, tamper-proof envelopes that were opened sequentially by an independent pharmacist. When an eligible subject was recruited, the pharmacist allocated the subject to the designated treatment group, maintaining blinding. Ascorbic acid and 0.9% saline were prepared by the independent pharmacist and had an identical appearance. All staff and participants were blinded to treatment allocation.
Data collection
Baseline demographic data were collected including medical history. All participants underwent transperitoneal open AAA repair via midline laparotomy. Anaesthesia was provided via a standardized technique.

A summary of events and measurements performed is shown in Figure 1.

Measurements
Plasma and serum samples were obtained from arterial blood samples taken from the indwelling arterial catheter. Blood samples were centrifuged at 2000 rpm for 10 minutes at 10°C and then samples were frozen at -80°C until analysis. Urine samples were collected and frozen at -80°C until analysis.

Plasma Von Willebrand Factor (vWF) level was measured by ELISA as previously described [11]. Soluble forms of Intercellular adhesion molecule (sICAM)-1, vascular cell adhesion molecule (sVCAM)-1, endothelial (sE)-Selectin and platelet (sP)-Selectin were measured using a Fluorokine® MAP multiplex kit (R&D Systems, Minneapolis, MN, USA) with a BioRad BioPlex™ analyser (Luminex Corp., Austin, TX, USA). Interleukins IL-6 and IL-8 were measured using a cytometric bead array (R&D Systems, Abingdon, UK) as previously described [28]. Serum highly sensitive C Reactive Protein (hsCRP) analysis was performed using the Quantex CRP ultra sensitive quantitative system (ILab Chemistry Systems, Instrumentation Laboratory Company, Lexington, Mass). Serum aqueous phase lipid hydroperoxides were measured using the ferrous iron/xylene orange (FOX) assay as previously described [29]. Plasma 8-iso-Prostaglandin F2α was measured using a direct enzyme immunoassay kit (Assay Designs Inc., Ann Arbor, Michigan, USA) with a BioRad BioPlex™ analyser (Luminex Corp., Austin, TX, USA). To measure plasma ascorbic acid, plasma was mixed with 5% meta-phosphoric acid (MPA) to stabilise ascorbic acid and then measured on a Cobas FARA centrifugal analyser with a fluorescent attachment according to Vuilleumier & Keck [30]. To determine urinary ACR, albumin was measured in urine using a commercially available immunoturbidimetric assay containing antibody specific for human albumin (Randox Laboratories Ltd. Crumlin, Co. Antrim, UK). Creatinine was measured using a modified Jaffe method as previously described (Roche Diagnostics, IN, USA) [31].

PWA was used to assess systemic endothelial function as previously described [14]. This was performed with the SphygmoCor Mx System (AtCor Medical, Sydney, Australia). An indwelling 20G radial arterial catheter was used to obtain a calibrated peripheral arterial pressure waveform. The central aortic waveform was derived from the peripheral arterial waveform using a validated transfer function [32,33]. Aortic
augmentation is defined as the difference between the first systolic peak (caused by left ventricular contraction) and second systolic peak (caused by wave reflection) and the augmentation index (Alx) is this difference expressed as a percentage of the central pulse pressure. Alx is calculated and corrected to a heart rate to 75 beats/min. The Alx following nebulised salbutamol 2.5mg measures endothelium dependent vasodilation (EDV) [34].

Pulmonary Dead-Space Fraction (Vd/Vt) was measured using volumetric capnography utilizing the NICO2 Monitor (Philips Respironics UK Ltd., Tangmere, UK) to calculate the partial pressure of expired CO2. This is then used in the Enghoff modification of the Bohr equation [35]. This method has been validated in a cohort of patients with acute lung injury [36].

Exhaled Breath Condensate (EBC) pH as a measure of alveolar neutrophilic inflammation was measured in EBC collected using an RTube™ (Respiratory Research, Austin, TX, USA) as previously described [37]. Exhaled breath condensate pH was measured using an Orion 9803BN micro pH electrode and digital pH meter (Thermo Scientific, Waltham, MA, USA) immediately after collection.

Statistics
Proportions were used as descriptive statistics for categorical variables. Mean (standard deviation) or median (interquartile range) were used as appropriate after testing for normality with the Kolmogorov-Smirnov test. Between group categorical variables were compared using Fishers exact test and continuous variables with an unpaired Student’s t-test or Mann-Whitney U test as appropriate. Comparison of variables before and after open AAA repair was made using a paired Student’s t-test or Wilcoxon matched pairs test as appropriate. Statistical analysis was performed and graphs generated using Prism 5 for Mac OS X, version 5.0b (GraphPad Software Inc.). A P value of <0.05 was considered significant.

Power calculation
The sample size calculation was determined using data from a previous study examining plasma vWF concentration in elective open AAA repair patients [12]. Based on these data, mean (standard deviation) vWF concentrations of 175(56) and 125(40) U/dl were assumed for patients receiving placebo and ascorbic acid respectively. On this basis 31 patients were required to complete the study. On the basis of assumed unequal variance between the groups, 18 patients were allocated to receive placebo and 13 to receive ascorbic acid. This provided 80% power to detect a statistical difference if the true difference was as suggested above. This calculation assumed that a two-tailed t-test at a 5% significance level was applied.

Results
Forty three patients were screened over an 18 month period. Twelve patients were excluded. Thirty-one participants received study drug, completed the study and were included in the analysis. Thirteen patients received ascorbic acid and 18 received placebo (Figure 2).
Baseline characteristics were similar in both groups. The duration of ischaemic injury caused by the aortic clamp was similar between groups (Table 1). Mean arterial pressure fell intra-operatively from 101 (17) mmHg to 85 (15) mmHg in the ascorbic acid group (p = 0.03) and from 101 (16) mmHg to 82 (15) mmHg in the placebo group (p < 0.001) but there were no differences between groups either pre- or post-operatively. Ascorbic acid levels measured four hours following removal of the aortic clamp were higher in the ascorbic acid group compared to placebo (104.4 (84.8, 132.7) μmol-1 vs 18.2 (6.2, 34.5) μmol-1, p < 0.001).

Effects of ascorbic acid on endothelial function
Plasma VWF levels were similar between groups both before and after open AAA repair. Similarly there were no differences in EDV between groups either pre- or post-operatively (Table 2). Urinary ACR was significantly higher in both the placebo (p < 0.001) and ascorbic acid (p = 0.01) groups after AAA repair, however there were no differences between the groups (Figure 3). There were no significant changes in pulmonary deadspace following open AAA repair (Table 2).

Effects of ascorbic acid on soluble adhesion molecules
Plasma sICAM-1 fell within both the placebo (p < 0.001) and ascorbic acid (p = 0.005) groups after open AAA repair, There was no difference between placebo and ascorbic
acid groups pre-operatively (p = 0.1) however plasma sICAM-1 was higher in the ascorbic acid group post-operatively (p = 0.03 vs placebo, Figure 4A). Plasma sVCAM-1 was similar pre and post open AAA repair in both groups and there was no difference between groups (Figure 4B). Plasma sE-Selectin fell post-operatively within both the

| Table 1 Demographic, historical and pre-operative physiological parameters |
|-------------------------------------------------|-----------------|------------------------------------------------|
| **Placebo group** | **Ascorbate group** |
| **Mean (SD), Median (IQR) or n (%)** | **Mean (SD), Median (IQR) or n (%)** |
| **Demographics** | | |
| Age (years) | 70.4 (7.4) | 73.2 (5.9) |
| Height (m) | 1.71 (0.09) | 1.71 (0.05) |
| Weight (kg) | 77.1 (11.1) | 78.2 (7.7) |
| BMI (kgm\(^{-2}\)) | 26.4 (3.3) | 26.8 (2.8) |
| Gender (% male) | 17 (94%) | 11 (85%) |
| **Past medical history** | | |
| IHD | 8 (44%) | 4 (31%) |
| Atrial Fibrillation | 0 (0%) | 2 (15%) |
| Hypertension | 16 (89%) | 12 (92%) |
| Cerebrovascular Disease | 1 (6%) | 1 (8%) |
| **Cardiovascular risk factors** | | |
| Smoking | 4 (22%) | 5 (38%) |
| Hypercholesterolaemia | 10 (56%) | 6 (46%) |
| Hypertension | 16 (89%) | 12 (92%) |
| Diabetes | 1 (6%) | 0 (0%) |
| **Drug history** | | |
| Statin | 12 (67%) | 9 (69%) |
| ACE Inhibitors | 5 (28%) | 3 (23%) |
| β Blockers | 7 (39%) | 6 (46%) |
| Diuretics | 2 (11%) | 3 (23%) |
| Anticoagulants | 5 (28%) | 5 (38%) |
| **Baseline physiological parameters** | | |
| Respiratory Rate (min\(^{-1}\)) | 14 (12.15) | 12 (12.15) |
| Temperature (°C) | 36.6 (0.33) | 36.8 (0.38) |
| Heart Rate (min\(^{-1}\)) | 63 (10.3) | 60 (13.7) |
| Peripheral SBP (mmHg) | 145.2 (24.9) | 150.5 (29.6) |
| Peripheral DBP (mmHg) | 77 (12.4) | 76 (11.7) |
| **Haematological and biochemical indices** | | |
| Haemoglobin (gdl\(^{-1}\)) | 13.7 (1.2) | 13.7 (1.1) |
| Leucocyte Count (x10\(^9\)ml\(^{-1}\)) | 7.3 (1.7) | 7.3 (1.8) |
| Platelet Count (x10\(^9\)ml\(^{-1}\)) | 201 (54) | 211 (64) |
| Urea (mmoll\(^{-1}\)) | 7.8 (2.1) | 6.7 (1.8) |
| Creatinine (μmoll\(^{-1}\)) | 96 (31) | 101 (30) |
| **Surgical details** | | |
| Ischaemic Time (mins) | 60.5 (16.9) | 64.6 (17.6) |

SD, Standard Deviation, IQR, Interquartile Range, BMI, Body Mass Index, SBP, Systolic Blood Pressure, DBP, Diastolic Blood Pressure, IHD, Ischaemic Heart Disease, ACE, Angiotensin Converting Enzyme.
placebo (p < 0.001) and ascorbic acid (p = 0.002) groups, although there was no difference between the groups (Figure 4C). Plasma sP-Selectin fell post-operatively within the placebo (p = 0.0001) but not the ascorbic acid (p = 0.41) groups, although there was no difference between the groups (Figure 4D).

### Effects of ascorbic acid on systemic and pulmonary markers of inflammation

Plasma CRP was similar pre and post open AAA repair in both groups and there was no difference between groups (Table 2). Plasma IL-6 increased during the study period in the placebo (p < 0.001) and ascorbic acid (p < 0.001) groups although there was no difference between the groups (Figure 5A). Similarly plasma IL-8 also increased significantly in both placebo (p < 0.001) and ascorbic acid (p < 0.001) groups but again there was no difference between the groups (Figure 5B).

### Table 2 Comparison of biomarkers in ascorbic acid and placebo groups pre- and post-operatively

|                      | Pre operative parameters | Post operative parameters |
|----------------------|--------------------------|---------------------------|
|                      | Placebo group            | Ascorbate group           | Placebo group   | Ascorbate group |
|                      | n = 18                   | n = 13                    | n = 18          | n = 13          |
|                      | Mean (SD), Median (IQR)  | Mean (SD), Median (IQR)   | Mean (SD), Median (IQR) | Mean (SD), Median (IQR) |
| **Endothelial function** |                          |                           |                 |                 |
| vWF (% Control)      | 141 (61)                 | 139 (60)                  | 158 (78)        | 169 (65)        | 0.68 |
| EDV (%)              | 3.5 (1.8, 5.3)           | 3.0 (1.5, 5.5)            | 6.0 (2.5, 8.5)  | 4.0 (2.0, 6.0)  | 0.32 |
| Vd/Vt                | 0.56 (0.06)              | 0.54 (0.05)               | 0.56 (0.06)     | 0.54 (0.06)     | 0.74 |
| **Systemic and pulmonary inflammatory mediators** |                          |                           |                 |                 |
| Serum hsCRP (mg/L)   | 2.14 (0.97, 5.75)        | 1.83 (1.15, 4.49)         | 2.85 (1.45, 4.63)| 1.96 (1.13, 4.23)| 0.27 |
| Arterial pH          | 7.38 (0.04)              | 7.40 (0.05)               | 7.32 (0.08)     | 7.29 (0.06)     | 0.20 |
| **Pulmonary function** |                          |                           |                 |                 |
| PaO₂:FIO₂ ratio (kPa) | 59.6 (47.8, 81.1)        | 59.6 (46.5, 97.7)         | 45.3 (28.3, 49.4)| 42.5 (32.7, 51.4)| 0.79 |

SD, Standard Deviation, IQR, Interquartile Range, EDV, Endothelium-dependent vasodilatation, vWF, von Willebrand Factor, Vd/Vt, Pulmonary Deadspace Fraction, EBC, Exhaled Breath Condensate, CRP, C Reactive Protein.
EBC pH decreased in both the placebo (p = 0.008) and ascorbic acid (p = 0.002) groups post-operatively although there was no difference between the groups (Figure 6). Systemic arterial pH also decreased in both the placebo (p < 0.001) and ascorbic acid (p = 0.005) groups post-operatively although there was no difference between the groups (Table 2). There was no significant correlation in the change in systemic arterial pH and EBC pH in either the placebo (p = 0.52, $r^2 = 0.03$) or ascorbic acid (p = 0.23, $r^2 = 0.13$) groups.

**Effects of ascorbic acid on systemic oxidative stress**

Plasma lipid hydroperoxides decreased in the placebo group (p = 0.002) but not in the ascorbic acid group (p = 0.38). Furthermore post-operative lipid hydroperoxides were significantly higher in the ascorbic acid group (p < 0.001, Figure 7A). Plasma 8-isoprostane was similar pre and post open AAA repair in both groups and there was no difference between groups (Figure 7B).

**Effects of ascorbic acid on pulmonary function and clinical outcomes**

The PaO$_2$:FiO$_2$ ratio fell significantly in both placebo (p = 0.002) and ascorbic acid (p < 0.001) groups although there was no difference between groups (Figure 8).

Post-operative infections were diagnosed in 3 (17%) of the placebo group and in 2 (8%) of the ascorbate group (p = 0.62). Only 3 patients in each group required post-operative invasive ventilation and the duration of ventilation was similar between groups (p = 0.77). The duration of stay in critical care was similar between the placebo
and ascorbic acid groups (2.9 (3.5) days versus 2.3 (3.2) days, p = 0.64). Similarly there was no difference in hospital stay (10.2 (4.8) versus 8.8 (2.6) days, p = 0.37). There was one post-operative fatality in the placebo group. No serious adverse reactions related to the study drug occurred.

**Discussion**

We have found that open AAA repair caused significant changes in markers of systemic endothelial dysfunction as well as an increase in systemic and pulmonary inflammation, and a reduction in a marker of pulmonary function. However ascorbic acid therapy did not attenuate changes in these biomarkers following open AAA repair.

Our findings are in keeping with previous data showing increased urinary ACR and inflammation and with a decrease in PaO$_2$:FiO$_2$ ratio following open AAA repair [12,38]. In contrast to these findings however we did not see an increased serum CRP or increased plasma vWF. An increasing proportion of participants now receive treatment for co-morbid conditions such as statins. Statins have anti-inflammatory effects [28,39] and may modulate endothelial function modifying responses to open AAA surgery. We found no increase in pulmonary dead space fraction. It is possible that the injury was not sufficient to induce pulmonary endothelial dysfunction or that the time to post operative assessment was of insufficient duration. As part of the standardized anaesthetic protocol, maintenance was with sevoflurane which has been shown to protect the endothelium from ischaemia-reperfusion injury [40] and might have further attenuated any potential pulmonary endothelial injury.
The fall in EBC pH as a marker of alveolar neutrophilic inflammation was an interesting finding. This was associated with a decrease in the PaO₂:FiO₂ ratio. The fall in EBC pH in this study may reflect pulmonary inflammation given that there was no correlation found with this decrease and changes in systemic pH.

Ischaemia-reperfusion injury has been used to provoke acute lung injury (ALI) in animal models [41]. The obligate ischaemia-reperfusion injury of open AAA repair is associated with post operative pulmonary dysfunction [42]. A recent observational study
found that post-operative respiratory failure was associated with increased mortality [43]. Reflecting findings in ALI, we have shown open AAA repair is associated with local alveolar inflammation as well as systemic endothelial dysfunction and inflammation. Elevated plasma IL-6 and -8 levels are predictive of outcome in patients with ALI [44]. As a marker of systemic vascular permeability, urinary ACR has been shown to have an inverse relationship with PaO$_2$:FiO$_2$ ratio in a cohort of trauma patients [45]. These findings support the use of open AAA repair as a human model of ALI induced by systemic inflammation. However, in the present study mediators implicated in ALI such as vWF [11] were not elevated. It is possible that endothelial injury was not caused to a measurable level. In a murine model of ALI the administration of parenteral ascorbic acid (200 mg/ml) 30 minutes after a septic insult attenuated the inflammatory response and was associated with improved survival, pulmonary function and coagulation [21]. In this study Fisher and colleagues suggested that the protective effects of ascorbic acid are due to its pleotropic actions on multiple pathways and it is possible in the current study, a lack of benefit may be related to the limitations in biomarkers used.

We investigated a single 2 g bolus of intravenous ascorbic acid following induction of anaesthesia in this study. This dose was informed by previous research where pre-treatment with 2 g ascorbic acid was found to modulate the adverse haemodynamic effects of experimentally induced hyperglycaemia [46]. In addition ascorbic acid (2 g) has been shown to prevent hyperglycaemia-induced endothelial dysfunction in healthy human volunteers [47].

In the present study a decrease in plasma adhesion molecules was found. Haemodilution as part of intra-operative management could be potential mechanism for the reduction in soluble adhesion molecules as well as the lack of increase in serum hsCRP. However, as plasma IL-6 and IL-8 both increased, haemodilution is less likely. Comorbid treatment may also have influenced adhesion molecules expression. Both statins and β blockers may modify adhesion molecules expression. Human coronary endothelial cells treated with nebivolol in vitro have a decrease in VCAM-1, ICAM-1, E- and P-Selectin expression [48]. Interestingly in another study of open AAA repair there was a non-significant fall in both ICAM-1 and VCAM-1 [49]. This has been mirrored in an in vitro study of human aortic endothelial cells which showed exposure of these cells to hypoxia and subsequent reoxygenation did not upregulate surface expression or shedding of adhesion molecules [50].
There was no increase in markers of oxidative stress in the placebo group unlike in other studies. Prostaglandin F$_2\alpha$ is increased both on hospital arrival and during the perioperative period in patients with ruptured AAA repair [51]. Malondialdehyde, another marker of oxidative damage was increased at one and 24 hours post open AAA repair [52]. In a recent small observational study derivatives of reactive oxygen metabolites were used to define post-operative oxidative stress in patients undergoing aortic surgery. This showed that in those having open AAA repair this marker was no different at 24 hours after surgery, but was significantly elevated 1 week later [53]. This study had an earlier sampling time, older cohort of patients and aortic clamp times contributing to the different data between studies.

Ascorbic acid did not improve markers of endothelial function or attenuate the inflammatory response markers in this study. In previous research pretreatment with 2000mg parenteral ascorbic acid prevented arterial stiffness secondary to induced hyperglycaemia in healthy male volunteers [23]. In a study of 37 critically ill patients with burns the use of high dose ascorbic acid (66 mg/kg/hr) for 24 hours reduced fluid requirements, wound oedema, and severity of pulmonary dysfunction [25]. In a double-blind randomized placebo-controlled trial of 216 critically ill patients, enteral ascorbic acid (500 mg/day) and tocopherol (400 IU/day) was associated with a decrease in 8-isoprostane. The anti-oxidant treated group had improved 28-day mortality and more ventilator free days [54]. We found lipid hydroperoxides were increased with ascorbic acid. This increase in lipid peroxides was not seen in plasma 8-isoprostanes, another measure of oxidative stress. Lipid hydroperoxides can be affected by dietary factors not accounted for in the current study. Isoprostane levels however, are not affected by diet [55] and may be a better measure of oxidative stress [56]. Previous studies utilizing the FOX assay have indicated its lack of specificity for hydroperoxides [57]. However, in keeping with our findings, Bailey at al found 2000 mg ascorbic acid orally two hours before operation in patients undergoing major vascular surgery increased both lipid peroxides and plasma IL-6 [58]. Possible reasons for increased oxidative stress markers in this current study may relate to the timing of sampling and range of ischaemic times. It is possible that at the dose used in this study, ascorbic acid acted as a pro-oxidant with no beneficial effects on either the endothelium or measured mediators of inflammation.

There are numerous limitations in this study. The patient cohort was small increasing the risk of a type 2 error. Within the participants neither aneurysm size or anatomical location were described. Duration of aortic clamping was recorded but the position was not noted. Although the surgical approach and anaesthetic technique was standardised the quantities of transfused blood products and fluids were not compared. Similarly the need for cardiovascular support was not quantified. These confounding factors may have had a consequence on the resultant endothelial injury. Having taken measurements using a limited number of biomarkers of organ dysfunction up to only 4 hours following aortic clamping may increase the risk of a type 1 error.

**Conclusion**

In conclusion, open AAA repair caused increased markers of systemic endothelial dysfunction and inflammation with an associated fall in oxygenation. These findings
support the use of open AAA repair as a human model of ALI induced by systemic inflammation. Ascorbic acid administration did not improve the measured biomarkers and limited functional parameters observed.

Competing interests
MJD has received payments from Otsuka Pharmaceuticals for lectures. MS has financial interest in AstraZeneca DFM DWH. BAM no interests to declare. DFM and CMO K have received consultancy fees from Orion, GlaxoSmithKline and AstraZeneca and have research funding from GlaxoSmithKline for Acute Lung Injury. ISY has received funding for lectures from Astra Zeneca, Merck and Roche and is a member of the advisory committee on nutrition to Dept of Health UK.

Authors’ contributions
MJD, BAM, CMO, DFM, DWH: Study design and conduct. MJD, ISY: Laboratory analyses. MJD, BAM, DFM: Manuscript authors. MJD, MS: Data analyses. All authors read and approved the final manuscript.

Acknowledgements
We wish to acknowledge those patients and their families who agreed to participate in the study.

Funding
This study was funded by a research grant from the British Journal of Anaesthesia / RCoA. Equipment was provided by a grant from the Vascular Anaesthetic Society of Great Britain and Ireland. The research team also received a small grant from Revive, the Regional Intensive Care Unit Charity.

Attribution of Work
Centre for Infection and Immunity, The Queen’s University Belfast
Regional Intensive Care Unit, Royal Victoria Hospital, Belfast

Summary statement
A prospective randomized controlled trial of ascorbic acid in open AAA repair demonstrated pulmonary and systemic endothelial injury with increased systemic inflammation postoperatively. The administration of ascorbic acid did not attenuate biomarkers of endothelial damage.

Author details
1Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK. 2Centre for Infection and Immunity, The Queen’s University Belfast, First Floor, Health Sciences Building, 97 Lisburn Road, Belfast BT9 7BL, UK. 3Centre for Public Health, The Queen’s University Belfast, Belfast, UK. 4Regional Vascular Surgery Unit, Royal Victoria Hospital, Belfast, UK.

Received: 9 June 2014 Accepted: 24 March 2015
Published online: 01 July 2015

References
1. Bown M, Nicholson ML, Bell PRF, Sayers RD (2001) Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 22:485–495
2. McCord J (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159–163
3. Edrees WK, Lau LL, Young S, Smye MG, Gardiner KR, Lee B, Hannon RJ, Soong CV (2003) The effect of lower limb ischaemia-reperfusion on intestinal permeability and the systemic inflammatory response. Eur J Vasc Endovasc Surg 25:330–335
4. Morrow J, Roberts L (2002) The isoprostanes their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 166:525–530
5. Entman M, Youker K, Shappell S (1990) Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest 85:1497–1506
6. Shreenivas R, Koga S, Karakurum M (1992) Hypoxia mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface J Clin Invest 90:2333–2339
7. Karakurum M, Shreenivas R, Chen J, Pinsky D, Yan SD, Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K, Rot A, Nowygrod R, Stern D (1994) Hypoxic Induction of Interleukin-8 Gene Expression in Human Endothelial Cells. J Clin Invest 93:1564–1570
8. Malik A, Sultan S, Tumer S (2007) Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J Hum Hypertens 21:231–8
9. Pedrinelli R, Dell’Omo G, Pennino G (2001) Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 6:257–64
10. Norwood M, Sayers R (2005) Urinary Albumin:Creatinine Ratio (ACR) and the Prediction of Postoperative Complications After Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg 30:353–358
11. Ware LB, Eiser MD, Thompson BT, Parsons PE, Matthey MA (2004) Significance of von Willebrand factor in septic and non-septic patients with acute lung injury. Am J Resp Crit Care Med 170(7):766–772
12. Ritto D (2005) Randomized study comparing the effects of hydroxethyl starch solution with gelofusine on activated endothelium and the systemic AntiInflammatory response following aortic aneurysm repair. Eur J Vasc Endovasc Surg 30(5):520–524
13. Smith FC, Gosling P, Sanghera K, Green MA, Paterson IS, Shearman CP (1994) Microproteinuria predicts the severity of systemic effects of reperfusion injury following infrarenal aortic aneurysm surgery. Ann Vasc Surg 8:1–5
14. Duffy MJ, Mullan BA, Craig TR, Shyamsundar M, MacSweeney RE, Thompson G, Stevenson M, McAuley DF (2011) Impaired endothelium-dependent vasodilatation is a novel predictor of mortality in intensive care. Crit Care Med 39(4):629–635
15. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA (2002) Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 346:1281–1286
16. Wilson J (2009) Mechanism of action of vitamin C in sepsis: Ascorbate modulates redox signaling in endothelium. Biofactors 35(1):15–13
17. Frei B, England L, Ames B (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 86:3767–3781
18. Pietri S, Seguin JR, d’Arbigny P, Culcasi M (1994) Ascorbyl free radical: a noninvasive marker of oxidative stress in human open-heart surgery. Free Radiac Biol Med 16:523–528
19. Lassnigg A, Puruz A, Barker R, Keznicki P, Manhart N, Roth E, Hiernayr M (2003) Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 90:148–154
20. Fain O, Paries J, Jacquart B, LeMoel G, Kettaneh A, Stirnemann J, Heron C, Stibon M, Taleb C, Letellier E, Betarib, Gattegno L, Thomas M (2003) Hypovitaminosis C in hospitalized patients. Eur J Intern Med 14:419–425
21. Fisher BJ, Krausauskas D, Martin EJ, Farkas D, Wegenlin JA, Brophy D, Ward RR, Voelkel NF, Fowler AA III, Natarajan R (2012) Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol 303:L20–L32
22. Ware L, Matthay M (2000) The acute respiratory distress syndrome. New Eng J Med 342(18):1334–1349
23. Mullan BA, Ennis CN, Fee HJ, Young IS, McCance DR (2004) Protective effects of ascorbic acid on arterial haemodynamics during acute hyperglycaemia. Am J Physiol Heart Circ Physiol 287:H1262–68
24. Marshall J (2008) Sepsis: rethinking the approach to clinical research. J Leukoc Biol 83:471–482
25. Tanaka H, Matsuda T, Miyagantani Y, Yukoka T, Maysuda H, Shimazaki S (2000) Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg 135:326–331
26. Wu F, Tymk K, Wilson J (2008) iNOS expression requires NAPDH oxidase-dependent redox signaling in microvascular endothelial cells. J Cell Physiol 217:207–214
27. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2004) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111:1201–1209
28. Shyamsundar M, McKewon SW, O’Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF (2009) Simvastatin Decreases Lipopolyasaccharide-induced Pulmonary Inflammation in Healthy Volunteers. Am J Respir Crit Care Med 179:1107–1114
29. Jiang Z, Hunt J, Wolff S (1992) Ferrous ion oxidation in the presence of xylene orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem 202(2):382–389
30. Vuillemier J (1989) Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. J Micronut Analysis 5:25–34
31. Junge W, Wilke B, Halabi A, Klein G (2004) Determination of reference intervals for serum creatinine, creatinine and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 344:137–148
32. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ (1998) Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol 32(Suppl 3):S53–S57
33. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, Br J Anaesth 90:148–154
34. Moloney ED, Mumby SE, Gajdocsi R, Cranshaw JH, Kharitonov SA, Quinlan GJ, Griffiths MJ (2004) Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery. Am J Resp Crit Care Med 169:64–69
35. Kallet RH, Daniel BM, Garcia O, Matthay MA (2005) Accuracy of physiologic dead space measurements in patients with acute respiratory distress syndrome using volumetric capnography: comparison with the metabolic monitor method. Respir Care 50(4):462–467
36. Moloney ED, Mummy SE, Gajdocci R, Cranshaw JH, Kharitonov SA, Quinlan GJ, Griffiths MJ (2004) Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery. Am J Respir Crit Care Med 169:64–69
37. Rittoo D, Gosling P, Burnley S (2004) Randomized study comparing the effects of hydroxyethyl starch solution with gelofusine on pulmonary function in patients undergoing abdominal aortic aneurysm surgery. Br J Anaesth 92:61–66
38. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O’Kane CM, Elborn JS, McAuley DF (2011) A randomized clinical trial of hydroxyethylglutanyl-coenzyme A reductase inhibition for acute lung injury (The HARP Study). Am J Resp Crit Care Med 183(5):620–626
39. Anneckte T, Chappell D, Chen C, Jacob M, Welsch U, Sommerhoff CP, Rehm M, Conzen PF, Becker BF (2010) Sevoflurane preserves the endothelial glycocalyx against ischaemia-reperfusion injury. Br J Anaesth 104(4):414–421
40. Moloney ED, Mumby SE, Gajdocci R, Cranshaw JH, Kharitonov SA, Quinlan GJ, Griffiths MJ (2004) Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery. Am J Resp Crit Care Med 169:64–69
41. Atitio D, Gosling P, Burnley S (2004) Randomized study comparing the effects of hydroxyethyl starch solution with gelofusine on pulmonary function in patients undergoing abdominal aortic aneurysm surgery. Br J Anaesth 92:61–66
42. Annecke T, Chappell D, Chen C, Jacob M, Welsch U, Sommerhoff CP, Rehm M, Conzen PF, Becker BF (2010) Sevoflurane preserves the endothelial glycocalyx against ischaemia-reperfusion injury. Br J Anaesth 104(4):414–421
43. Rutkowska K, Dressler JD, Carpenter JP, Fairman RM, Woo NY (2011) Predictors of decreased short- and long-term survival following open abdominal aortic aneurysm repair in a large contemporary series. J Vasc Surg 54(5):1237–43
44. Meduri GU, Healdey S, Kohler G, Stentz F, Tolley E, Umbreger R, Leeper R (1995) Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Chest 107:1062–1073

45. Gosling P, Sanghera K, Dickson G (1994) Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma 36:477–81

46. Mullan BA, Ennis CN, Fee HJP, Young IS, McCance DR (2005) Pretreatment with intravenous ascorbic acid preserves endothelial function during acute hyperglycaemia. Clin Exp Pharmacol Physiol 32(5–6):340–345

47. Mullan BA, Ennis CN, Fee HJP, Young IS, McCance DR (2004) Protective effects of ascorbic acid on arterial hemodynamics during acute hyperglycaemia. Am J Physiol Heart Circ Physiol 287:1262–1268

48. Wolf SC, Sauter G, Preyer M, Poerner T, Kempf VA, Risler T, Brehm BR (2007) Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 19(1–4):129–136

49. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Reichart B, Peter K, Becker BF (2007) Shedding of the endothelial glycolcalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 116:1896–1906

50. Maurus CF, Schmidt D, Schneider MKG, Turina MI, Seebach JD, Zund G (2003) Hypoxia and reoxygenation do not upregulate adhesion molecules and natural killer cell adhesion on human endothelial cells in vitro. Eur J Cardiothorac Surg 23:976–983

51. Lindsay TF, Luo XP, Lehotay DC, Rubin BB, Anderson M, Walker PM, Romaschin A (1999) Ruptured abdominal aortic aneurysm, a “two-hit” ischemia/reperfusion injury: Evidence from an analysis of oxidative products. J Vasc Surg 30:219–228

52. Papalambros E, Sigala F, Georgopoulos S, Parkevass K, Anreadou I, Menenakos X, Sigalas P, Papalambros AL, Vourliotakis G, Giannopoulos A, Bakoyiannis C, Bastounis C, Bastounis E (2007) Malondialdehyde as an indicator of oxidative stress during abdominal aortic aneurysm repair. Angiology 58(4):477–482

53. Kanaka Y, Inagaki E, Hanaeha S, Masaki H, Tanemoto K (2010) Analysis of Reactive Oxygen Metabolites (ROMs) after Cardiovascular Surgery as a Marker of Oxidative Stress. Acta Med Okayama 64(5):323–330

54. Cirri E, Ligoueri A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignolosa O, Vietri MT, Molinari AM, Sica V, Della Corte F, Napoli C (2004) The Beneficial Effects of Antioxidant Supplementation in Enteral Feeding in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Anesth Analg 99:857–863

55. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB (1999) Urinary isoprostan e excretion is not confounded by the lipid content of the diet. FEBS Lett 459:259–262

56. Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142:231–255

57. Yin H, Porter N (2003) Specificity of the ferrous oxidation of xylenol orange assay: analysis of autoxidation products of cholesteryl arachidonate. Anal Biochem 313(2):323–330

58. Bailey DM, Raman S, McEneny J, Young IS, Panham KL, Hullin DA, Davies B, McKeehan G, McCord JM, Lewis MH (2006) Vitamin C prophylaxis promotes oxidative lipid damage during surgical ischemia–reperfusion. Free Radic Biol Med 40:591–600

Submit your manuscript to a [SpringerOpen](https://www.springeropen.com) journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at [springeropen.com](https://www.springeropen.com)